Redeye: Immunicum - Approaching prime time

While we adjust our base case down to reflect dilution from the new capital, we continue to see significant potential in the stock.

Read more and download the Research Update: http://bit.ly/2HyrvQh

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/